Protea Biosciences 10-Q 21 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 21, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	Protea Biosciences Group, Inc.
Entity Central Index Key	1,335,103
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PRGB
Entity Common Stock, Shares Outstanding		149,286,707

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 0	$ 6,450
Accounts receivable, less allowance for doubtful accounts of $26,400 and $3,000 as of September 30, 2016 and December 31, 2015, respectively	339,963	195,823
Inventory	145,612	111,087
Prepaid expenses	70,701	98,231
Total current assets	556,276	411,591
Property and equipment, net	2,757,571	2,626,907
Deposits and other noncurrent assets	19,041	5,248
Total Assets	3,332,888	3,043,746
Current liabilities
Current maturities on short and long-term debt, net of discount	4,086,145	1,323,594
Accounts payable	1,891,273	1,338,367
Bank overdraft	233,246	0
Bank line of credit	3,000,000	3,000,000
Obligations to stockholders, net of discount	2,710,220	2,574,500
Derivative liabilities	4,929,660	962,401
Other current liabilities	551,249	391,308
Total current liabilities	17,401,793	9,590,170
Long-term debt, net of current maturities	1,837,593	1,726,158
Total Liabilities	19,239,386	11,316,328
Commitments and Contingencies
Stockholders’ Deficit
Preferred stock ($0.0001 par value; 10,000,000 shares authorized; none issued or outstanding as of September 30, 2016 and December 31, 2015)	0	0
Common stock ($0.0001 par value; 250,000,000 shares authorized; 134,226,310 and 133,146,250 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively)	13,423	13,315
Additional paid-in capital	72,088,973	71,311,572
Accumulated deficit	(88,008,940)	(79,597,608)
Accumulated other comprehensive income	46	139
Total Stockholders’ Deficit	(15,906,498)	(8,272,582)
Total Liabilities and Stockholders’ Deficit	$ 3,332,888	$ 3,043,746

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 26,400	$ 3,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	134,226,310	133,146,250
Common stock, shares outstanding	134,226,310	133,146,250

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Gross revenue	$ 519,908	$ 422,688	$ 1,577,010	$ 1,271,293
Cost of revenue	(468,823)	(209,802)	(1,162,803)	(525,571)
Gross profit	51,085	212,886	414,207	745,722
Selling, general and administrative expenses	(1,449,312)	(1,505,613)	(4,441,855)	(5,296,181)
Research and development expenses	(96,563)	(301,256)	(468,674)	(990,621)
Loss from operations	(1,494,790)	(1,593,983)	(4,496,322)	(5,541,080)
Other income (expense)
Gains from sales of investment	190,000	0	1,502,100	0
Gain (loss) on disposal of assets	(10,010)	(4,624)	(10,521)	51,607
Gain from insurance recovery	0	0	45,952	0
Interest expense	(963,295)	(663,863)	(1,486,969)	(1,154,804)
Debt conversion inducement cost	0	0	0	(60,419)
Change in fair value of derivative liabilities	(3,240,442)	(45,995)	(3,967,259)	(882,177)
Other income (expense)	346	1,424	1,687	7,427
Total other income (expense)	(4,023,401)	(713,058)	(3,915,010)	(2,038,366)
Loss before income taxes	(5,518,191)	(2,307,041)	(8,411,332)	(7,579,446)
Provision for income taxes	0	0	0	0
Net loss	(5,518,191)	(2,307,041)	(8,411,332)	(7,579,446)
Foreign currency translation adjustment	131	20	(93)	285
Total comprehensive loss	$ (5,518,060)	$ (2,307,021)	$ (8,411,425)	$ (7,579,161)
Weighted average number of shares of Common stock outstanding - basic and diluted (in shares)	133,824,867	115,839,765	133,605,888	105,923,915
Net loss per share - basic and diluted (per shares)	$ (0.04)	$ (0.02)	$ (0.06)	$ (0.07)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - 9 months ended Sep. 30, 2016 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Balance at Dec. 31, 2015	$ (8,272,582)	$ 0	$ 13,315		$ 71,311,572	$ (79,597,608)	$ 139
Balance (in shares) at Dec. 31, 2015		0	133,146,250
Issuance of common stock upon conversion of accrued interest	92,841	$ 0	$ 37		92,804	0	0
Issuance of common stock upon conversion of accrued interest (in shares)		0	371,364
Issuance of common stock for services	150,000	$ 0	$ 60		149,940	0	0
Issuance of common stock for services (in shares)		0	600,000
Issuance of common stock with short-term convertible note	27,174	$ 0	$ 11		27,163	0	0
Issuance of common stock with short-term convertible note (in shares)		0	108,696
Warrants issued with short-term convertible notes	265,093	$ 0	$ 0		265,093	0	0
Warrants to be issued to Placement Agent	60,219	0	0		60,219	0	0
Anti-dilution shares to be issued	6,878	0	0		6,878	0	0
Stock-based compensation	175,304	0	0		175,304	0	0
Net loss	(8,411,332)	0	0		0	(8,411,332)	0
Foreign currency translation adj.	(93)	0	0		0	0	(93)
Balance at Sep. 30, 2016	$ (15,906,498)	$ 0	$ 13,423		$ 72,088,973	$ (88,008,940)	$ 46
Balance (in shares) at Sep. 30, 2016		0	134,226,310	[1]
[1]	includes 57,488,533 warrants that contain an anti-dilution provision

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (8,411,332)	$ (7,579,446)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	496,487	532,616
Stock-based compensation	175,304	207,971
Issuance of common stock and warrants for services	150,000	221,923
Issuance of preferred and common stock for accrued interest	0	192,785
Accretion of original issue discount on short-term convertible notes	588,169	357,527
Accretion of debt issue costs on short-term convertible notes	390,995	324,747
Capitalized interest on short-term convertible notes	94,625	0
Debt conversion inducement cost	0	60,419
Capitalized interest on debt modification	0	34,596
(Gain) loss on disposal of assets	10,521	(51,607)
Gains from sales of investment	(1,502,100)	0
Gain from insurance recovery	(45,952)	0
Bad debt expense	0	119,230
Expense from the change in fair value of derivative liabilities	3,967,259	882,177
Net changes in certain assets and liabilities:
Accounts receivable	(144,140)	165,068
Prepaid expenses	27,530	(12,894)
Inventory	1,855	159,058
Other noncurrent assets	(13,793)	(93,014)
Accounts payable	552,906	175,543
Other current liabilities	252,781	(15,000)
Net cash used in operating activities	(3,408,885)	(4,318,301)
Cash flows from investing activities:
Purchase of and deposits on equipment	(87,269)	(74,868)
Purchase of equipment via lease (sales tax)	(32,972)	0
Proceeds from sale of equipment	51,416	154,154
Proceeds from sale of investment	1,502,100	0
Proceeds from insurance recovery	45,952	0
Net cash provided by investing activities	1,479,227	79,286
Cash flows from financing activities:
Proceeds from advances from stockholders	235,540	1,230,000
Payments on advances from stockholders	(94,376)	(25,000)
Proceeds from issuances of debt to stockholders	0	200,000
Payments on debt with stockholders	(5,444)	0
Proceeds from issuances of debt	2,886,000	2,000,000
Payments of debt issuance costs	(330,141)	(309,345)
Payments of issuance costs from short-term exchanged notes	(27,578)	0
Payments on debt	(662,783)	(167,393)
Payments on capital leases	(311,163)	(274,549)
Bank overdraft	233,246	0
Proceeds from sale of common stock	0	720,938
Proceeds from sale of preferred stock	0	575,042
Net cash provided by financing activities	1,923,301	3,949,693
Effect of exchange rate changes on cash	(93)	285
Net decrease in cash	(6,450)	(289,037)
Cash, beginning of period	6,450	322,877
Cash, end of period	$ 0	$ 33,840

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Description of Business and Basis of Presentation The Company Protea Biosciences Group, Inc. (referred to herein as “Protea,” “the Company,” “we,” “us” and “our”) is an emerging growth, molecular information company that has developed a revolutionary platform technology that enables the direct analysis, mapping and display of biologically active molecules in living cells and tissue samples. The technology platform offers new, unprecedented capabilities useful to the pharmaceutical, diagnostic, clinical research, agricultural and life science industries. “Molecular information” refers to the generation and bioinformatic processing of very large data sets, known as “big data,” obtained by applying the Company’s technology to identify and characterize the proteins, metabolites, lipids and other molecules which are the biologically active molecular products of all living cells and life forms. Our technology is used to improve pharmaceutical development and life science research productivity and outcomes, and to extend and add value to other technologies that are used in research and development, such as three-dimensional tissue models, biomarker discovery, synthetic biologicals and mass spectrometry. In particular, the Company believes that its ability to rapidly provide comprehensive molecular image-based datasets addresses a universal need of the pharmaceutical, diagnostic and clinical research and life science industries. The Company’s commercial development is centered on three lines of business: · Molecular information services – We believe that we are the commercial leader in providing multi-modal Mass Spectrometry Imaging (“MSI”), combining Laser Ablation Electrospray Ionization (“LAESI®”), Matrix Assisted Laser Desorption Ionization (“MALDI”) and optical microscopy. Our proprietary services enable the identification and quantitation of both small molecules (e.g., lipids and metabolites) and large molecules (e.g., proteins) and our services portfolio, inclusive of MSI, proteomics, metabolomics, lipidomics and bioinformatics is unique in the industry. Our clients include major pharmaceutical, chemical and biotechnology companies; · LAESI® instrument platform – We offer our proprietary LAESI® DP-1000 instrument, software and bioanalytical consumables to corporate and academic research laboratories, and; · Molecular diagnostics and clinical research – We apply our multi-modal MSI technologies and workflows in partnership with top-tier medical research institutions to co-develop new molecular diagnostic tests that the company believes can be used to improve the diagnosis and prognosis of cancer and provide requisite information useful in predicting the outcome of cancer treatment. Our current test development programs target the differential diagnosis and prognosis of malignant melanoma and the molecular profiling of subpopulations of cells in lung adenocarcinoma. Basis of Presentation The unaudited Consolidated Financial Statements include the accounts of Protea Biosciences Group, Inc. and its wholly-owned subsidiary, Protea Biosciences, Inc. In the opinion of management, these statements have been prepared on a basis consistent with the December 31, 2015 audited Consolidated Financial Statements and include all material adjustments, consisting of normal recurring adjustments and the elimination of material intercompany transactions and balances, necessary for a fair presentation of the Company’s consolidated financial position and results of operations for the interim periods presented. These unaudited, interim, Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include certain information and footnotes normally required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. The consolidated results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results of operations for the full fiscal year. These Consolidated Financial Statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 16, 2016 (“2015 Form 10-K”). Certain amounts included in the Company’s Consolidated Statement of Comprehensive Loss for the three and nine months ended September 30, 2015 have been reclassified to conform to 2016 classifications. Emerging Growth Company The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of Sections 14A(a) and (b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to hold a nonbinding advisory vote of shareholders on executive compensation and any golden parachute payments not previously approved. The Company has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our consolidated financial statements may not be comparable to companies that comply with public company effective dates. To the extent that we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures, and; (3) the requirement to provide only two years of audited financial statements instead of three years. Critical Accounting Policies Information with respect to the Company’s critical accounting policies which management believes are the most important to the portrayal of the Company’s reported results of operations and financial condition and that require management’s most difficult, subjective or complex judgements, often as the result of the need to make estimates about the effects of matters that are inherently uncertain, is contained in Part II, Item 7 of our 2015 Form 10-K. Recently Issued Accounting Pronouncements There were no changes to the recently issued accounting pronouncements as described in the consolidated financial statements included in our 2015 Form 10-K, except as related to the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Update 2015-03, “Interest–Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). This standard update, which was issued in April 2015, requires an entity to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability as opposed to an asset. Amortization of the costs will continue to be reported as interest expense. The update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015. Accordingly, the Company adopted ASU 2015-03 as of January 1, 2016; the adoption of this accounting standard update did not have a material impact on the Company’s consolidated financial statements. As mentioned above, as permitted under the JOBS Act, the Company has elected to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Going Concern The Company’s Consolidated Financial Statements included in this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings as well as sales of certain assets. Substantially all of the Company’s property and equipment are security for outstanding indebtedness. We will continue to require substantial funds to support our molecular information services business and advance global commercialization of our LAESI® instrument platform and service outstanding debt obligations, including scheduled interest and principal payments, and fulfilling payment obligations related to debt that has reached maturity. The Company has experienced negative cash flows from operations since inception. Since inception, our operations have been funded primarily through proceeds received from the issuance of debt and sale of equity securities in private placement offerings and, from time-to-time, sales of certain assets. Management intends to continue to meet the Company’s operating cash flow requirements by raising additional funds from the sale of equity or debt securities, the sale of certain assets, and possibly developing corporate development partnerships to advance our molecular information technology development activities by sharing the costs of development and commercialization. For example, we could also enter into a transaction such as a merger with a business that is complimentary to ours. We have also worked closely with various parties that financed our short- and long-term debt to obtain extensions and modifications that deferred or reduced amounts due under these obligations. Such extensions and modifications have included, in certain cases, the issuance of warrants. In addition, three members of the Company’s Board of Directors and the estate of a former board member guarantee payment of the Company’s outstanding bank line of credit. Such extensions, modifications and guarantees have been an important part of the Company’s ability to manage its liquidity and short-term capital resources. In addition, as part of these efforts, the Company has delayed payments to certain vendors and suppliers. As of September 30, 2016 the Company’s accounts payable balance of $ 1,947,739 1,608,934 1,303,710 1,301,710 233,246 10 October 15, 2016 On May 27, 2016, the Company filed a Form S-1 Registration Statement (“Form S-1”) with the SEC for a public offering of up to 3,100,000 15,000,000 On September 8, 2016, the Company entered into a note purchase agreement (the “Note Purchase Agreement”) with an “accredited investor” (as defined in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to which the investor purchased a 10 720,000 650,000 is in discussions with the investor regarding terms to extend the maturity date of the note and such investor has acknowledged that the Company is not currently in default under the note. See Note 18 Evaluation of Subsequent events for related information. As discussed under Note 9 Bank Line of Credit, the Company has reclassified the outstanding balance of its bank line of credit to current liabilities as of September 30, 2016. As of that date, the outstanding balance of the line of credit was $ 3,000,000 On September 9, 2016, the Company reached an agreement with the holders of certain short-term convertible notes with a principal amount totaling $ 1,892,500 1,987,125 10 March 31, 2017 91,250 95,813 On September 26, 2016, the Company issued a 20 156,250 March 26, 2017 125,000 107,500 On October 31, 2016, the Company received an advance from a related party, an officer of the Company and a Board of Director. To provide the Company with $ 255,000 In November 2016, the Company issued 14,927,066 29,854,132 1,119,530 We have sold most our investment in AzurRx BioPharma, Inc. (“AzurRx”) as a means of obtaining additional cash. We raised proceeds of $ 1,502,100 25 1.7 125,757 100,000 1.00 Certain of the Company’s outstanding financial instruments contain anti-dilution provisions that may be triggered by the issuance of Common Stock or financial instruments such as Preferred Stock and warrants that are convertible or otherwise exchangeable for shares of the Company’s Common Stock. As a result of the November 2016 share issuances anti-dilution provisions under certain outstanding financial instruments have been triggered. Under such provisions the Company shall issue 49,500,832 Aside from further issuances of its Common Stock, the Company is exploring other options for obtaining additional financial resources such as the issuances of short-term debentures and Preferred Stock. There can be no assurance that we will be successful in raising enough funds to sustain operations. Since inception, we have been successful in raising funds and selling certain assets to fund our operations and believe that we will be successful in obtaining the necessary capital resources to fund our operations going forward; however, there can be no assurances that we will be able to secure any additional funding or capital resources or the terms and conditions of any such arrangements. These factors raise substantial doubt about our ability to continue as a going-concern. The accompanying Consolidated Financial Statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

Gross Revenue

Gross Revenue	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	2. Gross Revenue Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Molecular information services $ 452,489 $ 206,601 $ 1,164,362 $ 596,309 LAESI® instrument platform 4,160 155,550 191,081 461,537 Research products 63,259 60,537 221,567 213,447 Gross revenue $ 519,908 $ 422,688 $ 1,577,010 $ 1,271,293

Sales of Investment

Sales of Investment	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block Supplement [Abstract]
Cost and Equity Method Investments Disclosure [Text Block]	3. Sales of Investment In the first quarter of 2016, the Company notified AzurRx of its intent to convert 71 0.0001 0.0001 The conversion rate was 24,393.65 shares of AzurRx Common Stock per share of AzurRx Preferred Stock. 1,731,949 1,016,941 637,100 550,000 675,000 140,000 190,000 As of September 30, 2016, the Company’s ownership interest in AzurRx included 125,757 1.7 100,000 1.00 The Company previously accounted for its investment in AzurRx using the “equity method.” However, considering the reduction in the Company’s interest in AzurRx during the three months ended March 31, 2016, the Company discontinued the use of the “equity method” of accounting for this investment and began accounting for the investment under the cost method (as fair market value for these shares was not readily determinable). On October 11, 2016, AzurRx completed an initial public offering (“AzurRx IPO”). As of that date, shares of AzurRx common stock are listed on the National Association of Securities Dealers Automated Quotations (“NASDAQ”) Capital Market under the ticker symbol “AZRX”.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	4. Derivative Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. However, the Company has certain financial instruments that are embedded derivatives associated with certain capital raises and common stock purchase warrants. The Company evaluates all of its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB Accounting Standards Codification 815-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. If the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity. See also Note 5 Fair Value of Financial Assets and Liabilities – Derivative Financial Instruments.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Derivatives and Fair Value [Text Block]	5. Fair Value of Financial Assets and Liabilities – Derivative Financial Instruments We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value and requires certain disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants) The Company has entered into certain financial instruments, such as convertible debentures and equity financing arrangements, which include variable conversion rates, include anti-dilution provisions (“down-round protection”) and detachable warrants that are: (i) not afforded equity classification; (ii) embody risks not clearly and closely related to host contracts, or; (iii) may be net-cash settled by the counterparty. Such derivative liabilities are recorded at fair value at the issuance date. Subsequent changes in fair value are recorded through the consolidated statement of comprehensive loss. For the Company, the Level 3 financial liability is the derivative liabilities related to certain Common Stock and warrants that include “down-round protection” that are valued using the “Monte Carlo Simulation” technique. While the majority of inputs are Level 2, this technique necessarily incorporates a capital raise assumption which is unobservable and, therefore, a Level 3 input. Expected life (years) Risk-free rate Volatility Probability of a capital raise Derivative liabilities 0.25 – 4.50 0.29% and 0.77% 79.52 % 100 % Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s derivative liabilities are related to certain Common Stock issuances that included “down-round protection”, warrants issued in conjunction with certain Common Stock and debt issuances, including warrants granted to the Placement Agent related to such issuances, that included “down-round protection”, and the variable conversion rate feature of certain short-term convertible debentures. See also Note 12 Debt, Note 13 Common Stock, and Note 15 Warrants. Fair value measurements as of September 30, 2016 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 4,097,278 $ – $ – $ 4,097,278 Derivative liabilities – Warrants 518,753 – – 518,753 Derivative liabilities – Convertible debentures 313,629 – – 313,629 Total $ 4,929,660 $ – $ – $ 4,929,660 Fair value measurements as of December 31, 2015 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 777,002 $ – $ – $ 777,002 Derivative liabilities – Warrants 185,399 – – 185,399 Total $ 962,401 $ – $ – $ 962,401 The Company’s assessment of the probability of future capital raises is considered to be high. Such capital raise activities are estimated to take place at levels that could possibly result in anti-dilution triggers—currently at $ 0.075 As a result of the November 2016 share issuances, anti-dilution provisions under certain outstanding financial instruments have been triggered, which was considered in the assumptions for future capital raise activity at September 30, 2016. See Note 18 Evaluation of Subsequent Events for additional information. Nine Months Ended September 30, 2016 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of January 1, 2016 $ 777,002 $ 185,399 $ – $ 962,401 Unrealized loss on derivative liabilities outstanding as of December 31, 2015 3,320,276 279,025 – 3,599,301 Fair value of variable conversion rate for convertible debentures issued in 2016 (a) – – 313,629 313,629 Fair value of derivative liabilities associated with other financial instruments issued in 2016 (b) – 54,329 – 54,329 Balance as of September 30, 2016 $ 4,097,278 $ 518,753 $ 313,629 $ 4,929,660 (a) See also Note 12 Debt (b) See also Note 15 Warrants

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	6. Net Loss per Share Basic and diluted loss per common share is computed based on the weighted average number of shares of Common Stock outstanding, or 133,824,867 133,605,888 115,839,765 105,923,915 98,285,387 86,556,934

Inventory

Inventory	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	7. Inventory September 30, 2016 December 31, 2015 Work-in-progress $ 135,902 $ 98,437 Finished goods 9,710 12,650 Total inventory $ 145,612 $ 111,087

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	8. Property and Equipment Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Equipment 5 – 10 years Vehicles 5 years Leasehold improvements Life of lease Software 3 years Property and equipment consists of the following: September 30, 2016 December 31, 2015 Lab equipment $ 6,526,399 $ 6,617,038 Computer equipment 552,423 540,212 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 Accumulated depreciation (4,725,229) (4,934,321) Property and equipment, net $ 2,757,571 $ 2,626,907 For the three and nine months ended September 30, 2016, depreciation expense was $ 177,359 496,487 176,561 532,366

Bank Line of Credit

Bank Line of Credit	9 Months Ended
	Sep. 30, 2016
Bank Line of Credit [Abstract]
Bank Line of Credit [Text Block]	9. Bank Line of Credit The Company has a line of credit with a bank that is authorized to $ 3,000,000 The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum. July 12, 2018 3,000,000 The Company’s line of credit with the bank requires the Company to adhere to certain customary covenants. For example, the bank can issue a default notice to the Company and accelerate payment of the outstanding balance if the Company fails to make a scheduled interest payment to the bank, is in default under any agreement with a third party which materially and adversely affects the Company’s property, operations or financial condition, or the Company does not make timely payments on property that is useful its business, including maintenance and repairs of such property. As mentioned above, the Company was not able to repay the September 2016 10 October 15, 2016 As of the date of this report, the Company has made all scheduled payments to the bank and the bank has not issued any notice to the Company regarding any default or possible default under the line of credit.

Obligations to Stockholders

Obligations to Stockholders	9 Months Ended
	Sep. 30, 2016
Loan Payable [Abstract]
Loans Payable to Stockholders [Text Block]	10. Obligations to Stockholders During the nine months ended September 30, 2016, the Company received advances equal to an aggregate of $ 235,540 94,375 52,500 2,574,500 2,710,220 1,111,556 1,598,664 On May 31, 2016, one of the outstanding interest-bearing promissory notes in the amount $ 200,000 12,500 12,500 5,444 194,556 4,864 On October 31, 2016, the Company received an advance from a related party, an officer of the Company and a Board of Director. To provide the Company with $ 255,000 See Note 13 Common Stock related to the conversion of accrued interest on promissory notes issued by the Company to Summit Resources, Inc. (“Summit”), an affiliate of Steve Antoline, a member of the Company’s Board of Directors, and accounts payable by the Company to Summit, into shares of Common Stock.

Other Current Liabilities

Other Current Liabilities	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	11. Other Current Liabilities September 30, 2016 December 31, 2015 Accrued expenses $ 158,850 $ 28,728 Accrued interest 117,130 108,731 Accrued warranty expense 54,293 50,000 Accrued payroll and benefits 148,890 124,183 Unearned revenue 72,086 79,666 Other payables and accrued expenses $ 551,249 $ 391,308

Debt

Debt	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt and Capital Leases Disclosures [Text Block]	12. Debt Short-Term Convertible Notes Issued in Second and Third Quarters 2016 and Related Exchange Notes In the second quarter of 2016, the Company issued a series of 20 1,950,000 1,560,000 448,750 415,000 605,000 481,250 390,000 10.0 0.25 0.25 85 On July 29, 2016, the Company sold to two Accredited Investors an aggregate face amount of $ 63,750 20 51,000 10 In addition, each of the investors received a three-year 75 0.325 731 which was recorded as a discount to the Summer 2016 Convertible Debentures and is being accreted to interest expense over the six-month term of the related notes. See also Note 15 Warrants. In connection with the issuance of the Summer 2016 Convertible Debentures, the Company paid to a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) that acted as the placement agent an aggregate of approximately $ 191,400 in cash compensation, representing fees and an expense allowance. In addition, the Company agreed to issue warrants to purchase an aggregate of approximately 1,409,625 0.25 per share and a term of three (3) years. The relative fair value of these warrants was estimated to be $ 3,077 which was recorded as a discount to the Summer 2016 Convertible Debentures. See also Note 15 Warrants. On September 9, 2016, the Company reached an agreement with certain holders of the Second Quarter 2016 Convertible Debentures pursuant to which such debentures were exchanged for new short-term convertible notes (the “Exchange Notes”). The Exchange Notes shall have a principal amount totaling $ 1,987,125 10 March 31, 2017 The relative fair value of the new warrants was estimated to be $ 287,792 September 2016 10% OID Secured Promissory Note On September 8, 2016, the Company entered into a Note Purchase Agreement with an Accredited Investor pursuant to which the investor purchased a 10 720,000 650,000 10 720,000 10 October 15, 2016 The Company’s obligations to repay and otherwise perform its obligations under the September 2016 10 As of the date of this report, the Company is in discussions with the investor regarding terms to extend the maturity date of the note and such investor has acknowledged that the Company is not currently in default under the note. If the Company is unable to successfully negotiate an extension to the note agreement, the Accredited Investor may assert all of its rights and remedies available under the Security Agreement and applicable law. See Note 18 Evaluation of Subsequent events for related information. September 2016 20% OID Note On September 26, 2016, the Company entered into a Subscription Agreement with an Accredited Investor pursuant to which the investor purchased a 20 156,250 March 26, 2017 125,000 156,250 0.25 85 468,750 0.325 1,792 which was recorded as a discount to the September 2016 20% OID Notes and is being accreted to interest expense over the six-month term of the notes. See also Note 15 Warrants. In connection with such issuance, the Company paid to a broker dealer registered with FINRA that acted as the placement agent an aggregate of approximately $ 15,000 109,375 239 Short-Term Convertible Note issued in March 2016 On March 4, 2016, the Company issued to St. George Investments LLC (“St. George Investments”), an Accredited Investor, a 23 500,000 150,000 5,000 108,696 27,174 1,637,500 0.75 70 The relative fair value of the St. George Investments Warrant was estimated at $ 12,773 27,174 38,019 51,613 104,947 150,000 On September 6, 2016, the March 2016 Convertible Note reached maturity and the Company paid $ 655,000 September 2016 10% OID Secured Promissory Note In connection with the sale of the March 2016 Convertible Note, the Company paid to a Placement Agent an aggregate of approximately $ 60,000 491,250 0.25 2,456 See Note 15 Warrants below related to the triggering of an anti-dilution provision included in the St. George Investments Warrant in May 2016. Convertible Promissory Notes with WVJITB The Company has outstanding two convertible promissory notes with the West Virginia Jobs Investment Trust Board (“WVJITB”). One is an 18-month note issued in March 2012 with a principal amount of $ 290,000 400,000 290,000 300,000 On December 31, 2015, the Company and WVJITB entered into an addendum whereby the maturity dates of both promissory notes were extended to March 31, 2016. In return for the extension, in February 2016, the Company granted WVJITB a five-year warrant to purchase 590,000 shares of the Company’s Common Stock at an exercise price of $ 0.40 590,000 200,000 300,000 0.50 10.0 2,478 On October 20, 2016, the WVJITB advised the Company that it would grant an additional extension for the maturity dates of both promissory notes. As of the date of this report, an addendum documenting the terms and conditions of the extension has not been finalized. Promissory Note with WVDO As of September 30, 2016, the Company was eight months is arrears on scheduled principal and interest payments on an outstanding note payable to the West Virginia Development Office (“WVDO”). The deferral amount totaled $ 64,278 16,070 In October 2016, the Company and WVDO reached a verbal agreement whereby the Company would make a payment to WVDO no later than November 30, 2016 for the deferred amount as well as scheduled payments for October and November 2016. Capital Leases In June 2016, the Company entered into a new four-year capital lease for three pieces of equipment that had a total estimated fair value of $ 549,543 From time to time, in the normal course of business, the Company enters into capital leases to finance equipment. As of September 30, 2016, the Company had seven capital lease obligations outstanding with imputed interest rates ranging from 5.04 9.45 1,868,809 September 30, 2016 December 31, 2015 Note Payable to the WVDO $ 92,873 $ 100,656 Note Payable to the WVEDA (a) 143,312 143,312 Note Payable to the WVIJDC (b) 139,229 139,229 Note Payable to the WVEDA (a) 572,148 572,148 Note Payable to the WVIJDC (b) 581,987 581,987 Note Payable to the WVJITB 290,000 290,000 Note Payable to the WVJITB 300,000 300,000 Note Payable to the WVEDA (a) 168,362 168,362 Convertible notes (c) 2,982,964 – Capital leases 1,048,122 754,058 Total 6,318,997 3,049,752 Less: current portion (4,086,145) (1,323,594) Less: unamortized original-issue discount (50,554) – Less: unamortized debt issuance costs (344,705) – Long-term portion $ 1,837,593 $ 1,726,158 (a) West Virginia Economic Development Authority (b) West Virginia Infrastructure and Jobs Development Council (c) Includes convertible notes with an outstanding balance of $ 1,987,125 Future required minimum Year Ended December 31: principal payments 2016 $ 4,049,767 2017 746,508 2018 514,743 2019 449,246 2020 and thereafter 558,733 Total $ 6,318,997

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Common Stock [Text Block]	13. Common Stock As of September 30, 2016, the Company was authorized to issue a total of 260,000,000 250,000,000 0.0001 10,000,000 0.0001 500,000,000 On December 1, 2015, the Company’s stockholders approved a Certificate of Amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of Common Stock, within a range of no less than one-for-fifteen (1:15) and no more than one-for-twenty-five (1:25), with such final ratio to be determined by the Board of Directors, in its sole discretion and with such reverse split to be effective at such time and date within one year after stockholder approval (the “Reverse Split”). See Note 18 Evaluation of Subsequent Events for additional information related to the expected ratio and timing for the Reverse Split. As of the date of this report, the Company’s Board of Directors had not enacted the Reverse Split and, therefore, the information presented in this report does not include the effects of any such transaction. See also Note 18 Evaluation of Subsequent Events related to the Company’s sale of Common Stock in November 2016. Conversion of Accrued Interest and Accounts Payable 33,333 8,060 450,000 0.40 945 In September 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 41,667 9,781 51,448 205,791 0.25 Advertising Services Agreement In March 2016, the Company entered into an agreement with an advertising firm for certain services to be rendered to the Company over an estimated ninety (90) day period (the “Media Advertising Agreement”). Besides cash compensation, the Media Advertising Agreement required the Company to issue 150,000 37,500 In July 2016, the Company renewed the agreement with such advertising firm for certain services to be rendered to the Company over an estimated ninety (90) day period. Besides cash compensation, the Media Advertising Agreement required the Company to issue 300,000 75,000 (this space intentionally left blank) Shares Price Estimated issued and per Gross fair value at Par Additional outstanding share proceeds issuance value paid-in capital Balance as of December 31, 2015 133,146,250 Various $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 Issuance (a) 371,364 $ 0.25 – 92,841 37 92,804 Issuance (b) 108,696 $ 0.25 – 27,174 11 27,163 Issuance (c) 600,000 $ 0.25 – 150,000 60 149,940 Balance as of September 30, 2016 134,226,310 (d) $ 58,393,786 $ 2,629,318 $ 13,423 $ 61,010,060 (a) See above under Conversion of Accrued Interest and Accounts Payable (b) Shares issued in conjunction with the March 2016 Convertible Note (see Note 12 Debt) (c) See above under Advertising Services Agreement (d) Includes 21,214,642

Stock Options and Stock-Based C

Stock Options and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Stock Based Compensation [Text Block]	14. Stock Options and Stock-Based Compensation In 2002, the Board adopted the 2002 Equity Incentive Plan (the “2002 Plan”) that governed equity awards to employees, members of the Board of Directors, and consultants of the Company. Under the 2002 Plan, 450,000 4,150,000 12,500,000 The types of awards permitted under the Plans include qualified incentive stock options (“ISO”), non-qualified stock options (“NQO”), and restricted stock. Each stock option shall be exercisable at such times and subject to such terms and conditions as the Board of Directors may specify. Stock options generally vest over four ( 4 10 Weighted average Weighted ave. remaining Stock options exercise price contractual life (years) Outstanding as of December 31, 2015 10,050,086 $ 0.69 7.26 Granted 3,350,000 $ 0.15 Exercised – $ – Cancelled or expired (1,594,216) $ 0.31 Outstanding as of September 30, 2016 10,800,086 $ 0.57 7.53 Exercisable as of December 31, 2015 4,938,664 $ 1.01 5.59 Exercisable as of September 30, 2016 5,204,317 $ 0.90 5.61 (this space intentionally left blank) Stock options outstanding Stock options exercisable Weighted Weighted Weighted average average average remaining contractual exercise exercise Exercise price Outstanding life (in years) price Exercisable price $ 0.15 3,250,000 – $ 0.25 1,573,336 576,264 $ 0.48 150,000 37,500 $ 0.50 79,000 79,000 $ 0.53 405,000 126,563 $ 0.55 3,312,000 2,354,240 $ 0.80 20,000 20,000 $ 1.25 150,000 150,000 $ 1.50 1,646,000 1,646,000 $ 2.00 214,750 214,750 $0.15 – $2.00 10,800,086 7.53 $ 0.58 5,204,317 $ 0.90 As of September 30, 2016, the total aggregate intrinsic value for stock options currently exercisable and stock options outstanding was estimated to be $ 0 0.12 Weighted average grant-date fair Stock options value (per option) Non-vested as of December 31, 2015 5,111,422 $ 0.153 Granted 3,350,000 $ 0.153 Forfeited (1,594,216) $ 0.314 Vested (1,038,437) $ 0.106 Non-vested as of September 30, 2016 5,828,769 $ 0.126 The fair value of non-vested stock options to be recognized in future periods is $ 674,803 2.72 175,304 207,971 Nine Months Ended September 30, 2016 2015 Selling, general, and administrative expense $ 164,860 $ 178,371 Research and development expense 10,443 29,600 Total stock-based compensation $ 175,303 $ 207,971 The weighted average grant-date fair value of stock options granted during the nine months ended September 30, 2016 was $ 0.095 0.31 Nine Months Ended September 30, 2016 2015 Weighted average risk-free interest rate 1.33 % 1.69 % Volatility factor 66.51 % 66.34 % Weighted average expected life (in years) 7.46 8 Dividend rate 0 % 0 % The Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar public companies considering their industry, stage of life cycle, size, and financial leverage. Given the Company’s limited history with stock options, the Company’s expected term is based on an average of the contractual term and the vesting period of the options (the SEC Staff Accounting Bulletin No. 110, “Simplified” method).

Warrants

Warrants	9 Months Ended
	Sep. 30, 2016
Warrants [Abstract]
Warrants [Text Block]	15. Warrants In connection with the issuance of the Summer 2016 Convertible Debentures and the September 2016 20% OID Note (see Note 12 Debt above), the Company granted each investor a three-year warrant to purchase shares of the Company’s Common Stock at an exercise price of $ 0.325 6,510,000 28,202 On September 9, 2016, the Company reached an agreement with holders of certain short-term convertible notes issued in May and June 2016, the Second Quarter 2016 Convertible Debentures, to exchange existing notes with new short-term convertible notes (the “Exchange Notes”). In addition to the Exchange Notes, such holders are exchanging their existing warrants for warrants that contain full-ratchet anti-dilution provisions. No additional changes are being made to such forms of warrants. The relative fair value of the new warrants was estimated at $ 233,345 54,447 The St. George Investments Warrant (see Note 12 Debt above for additional information related to this warrant and the related short-term convertible note) included an anti-dilution provision that required the Company to reduce the exercise price for the warrant for any subsequent issuances of Common Stock, or any instrument or securities that are convertible into or exercisable for shares of Common Stock, if the effective price for any such issuance was at an effective price per share that was less than the exercise price for the St. George Investments Warrant. Such a triggering event occurred upon issuance of the first of the Second and Third Quarter 2016 Convertible Debentures, each of which are convertible into shares of the Company’s Common Stock at $ 0.25 4,912,500 1,637,500 6,879 104,947 See Note 12 Debt and Note 13 Common Stock for information related to the issuance of warrants to Summit, WVJITB, and a placement agent for the purchase of 450,000 1,180,000 2,010,250 See also Note 18 Evaluation of Subsequent Events for information related to warrants issued in conjunction with the Company’s sale of Common Stock in early November 2016. In addition, see Note 18 Evaluation of Subsequent Events for information related to the triggering of certain anti-dilution provisions included in certain of the Company’s outstanding financial instruments, including the reduction of the exercise price for certain warrants. As of September 30, 2016, warrants to purchase 82,946,270 49,894 Weighted Weighted average average remaining exercise contractual life Warrants price (in years) Outstanding as of December 31, 2015 71,342,894 $ 0.77 2.375 Granted 15,803,751 $ 0.30 2.998 Exercised – $ – Cancelled or expired (4,200,375) $ 2.00 Outstanding as of September 30, 2016 82,946,270 (a) $ 0.61 1.984 (a) includes 57,488,533 Warrants outstanding Weighted Weighted average average remaining contractual exercise Exercise price Outstanding life (in years) price $ 0.250 12,317,895 $ 0.310 7,500,000 $ 0.325 6,510,001 $ 0.350 14,831,098 $ 0.360 2,845,000 $ 0.400 1,630,000 $ 0.450 1,730,000 $ 0.500 2,250,523 $ 0.750 11,065,144 $ 0.800 1,415,000 $ 1.100 19,054,350 $ 1.120 263,750 $ 2.000 138,800 $ 2.200 98,320 $ 2.250 1,296,389 $0.250 – $2.25 82,946,270 1.984 $ 0.61

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Legal Proceedings The Company currently is not a party to any material legal proceeding and has no knowledge of any material legal proceeding contemplated by any governmental authority or third party. The Company may be subject to a number of claims and legal proceedings which, in the opinion of our management, are incidental to normal business operations. In management’s opinion, although final settlement of these claims and suits may impact the financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, cash flows or results of operations. As of the date of this report, the Company had received three court summons for past due accounts payables. The claims total $ 213,032 Agreement with Landlord On November 4, 2016, the Company reached an agreement with the landlord for its Morgantown, West Virginia facility for payment of past-due rent. The agreement stipulates that the Company will pay the amount due as of October 31, 2016, $ 90,801 Warranty Reserve The Company provides for a one-year warranty with the sale of its LAESI® instruments. As the Company does not currently have sufficient historical data on warranty claims, the Company’s estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its products. As of September 30, 2016, and December 31, 2015, the Company had accrued warranty expense of $ 54,293 50,000 University License Agreements The Company has agreements with West Virginia University (“WVU”) and George Washington University (GWU) related to in-licensed technologies as follows: WVU The Company has entered into a License and Exclusive Option to License Agreement with the West Virginia University Research Corporation (“WVURC”), a nonprofit West Virginia corporation acting for and on behalf of WVU. Under the terms of this agreement, the WVURC has granted the Company an exclusive option to license technology from the laboratories of certain WVU principal investigators in the field of protein discovery, for therapeutic, diagnostic and all other commercial fields worldwide. Under the terms of this Agreement, the Company pays expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenue resulting from the sale of products and services that utilize the WVU subject technology. GWU I 4,765 20,299 10,934 31,145 118,046 79,292 In November 2012, the Company entered into a Patent License Agreement with GWU for technology developed in the laboratory of Akos Vertes Ph.D. The technology field is Laser Desorption/Ionization and Peptide Sequencing on Laser-Induced Silicon Microcolumn Arrays (“LISMA”) and Nanophotonic Production, Modulation and Switching of Ions by Silicon Microcolumn Arrays (Nanophotonic arrays, or “NAPA”). Under the terms of this agreement, the Company has an exclusive, worldwide license to make, have made, use, import, offer for sale and sell the licensed products. The Company is obligated to pay a license initiation fee of $ 25,000 12,500 20,000 30,000 7 5 50 6 4 1,500 2,500 3,500 6,000 2,500 5,500 8,500 6,000 In January 2014, the Company became a subcontractor to GWU in a multi-year project with the Defense Advanced Research Projects Agency (“DARPA”) to develop new tools and methods to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within thirty (30) days of exposure. We have commercialized a NAPA-based product out of this arrangement that is currently being sold to research laboratories performing small molecule analysis. This product is called REDIchip™ (an acronym for Resonance-Enhanced Desorption Ionization). COAST Project In 2014, the Company entered into an agreement with Omics2Image B.V. (“O2I”) related to the “Next Generation Ambient Imaging Mass Spectrometry for (Bio)polymers and Smart Materials” (the “COAST Project”). As part of this arrangement, the Company agreed to commit € 60,000 76,000 24,500

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Supplemental Cash Flow Information Cash paid for interest and income taxes During the nine months ended September 30, 2016, cash paid for interest totaled $ 190,752 193,942 The Company did not pay any income taxes during 2015 or the nine months ended September 30, 2016. Non-cash investing and financing activities Nine Months Ended September 30, 2016 2015 Equipment acquired under capital leases $ 605,227 $ 516,832 Debt converted to preferred stock $ – $ 550,260 Dividends paid in preferred stock $ – $ 156,056 Issuance of common stock upon conversion of accrued interest $ 92,841 $ – Issuance of common stock for services $ – $ – Issuance of common stock with short-term convertible notes $ 27,174 $ – Issuance of warrants with short-term convertible notes $ 31,747 $ – Warrants to be issued to Placement Agent $ 5,772 $ – Anti-dilution warrants to be issued $ 6,878 $ – Debt issuance costs $ 5,000 $ –

Evaluation of Subsequent Events

Evaluation of Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Evaluation of Subsequent Events Obligations to Stockholders Subsequent to September 30, 2016, the Company received an advance from a related party, an officer of the Company and a Board of Director. To provide the Company with $ 255,000 Subsequent to September 30, 2016, the Company received other advances totaling $ 83,000 9,164 3,039,056 Increase in Authorized Shares of Common Stock On October 21, 2016, the Company’s stockholders voted in favor of an increase in the Company’s authorized capitalization from 250,000,000 10,000,000 0.0001 500,000,000 10,000,000 0.0001 Sale of Common Stock At an initial closing held on November 3, 2016 (the “Closing”), the Company received an aggregate of $ 631,680 63 On November 18, 2016 (the “Closing”), the Company received an aggregate of $ 487,850 48.79 Pursuant to its private placement memorandum, dated as of October 31, 2016 (the “Memorandum”), the Company is offering, through a placement agent, a maximum of 500 10,000 5,000,000 133,333.33 0.0001 133,333.33 0.09 133,333.33 0.1125 66,666,667 133,333,334 The Company intends to consummate a 1-for-25 In connection with the Closings, the Company paid to the placement agent an aggregate of $ 152,384 4,231,120 0.09 In connection with the Closing, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with each of the Purchasers, which requires the Company to file a registration statement (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) registering for resale (i) all Common Stock issued to the Purchasers as part of the Units, (ii) all shares of Common Stock issuable upon exercise of the Investor Warrants and the warrants issued to the placement agent, and (iii) all shares of Common Stock issued to legal counsel for services rendered in connection with the Closing. If the Registration Statement is not declared effective by the SEC within the specified deadlines set forth in the Registration Rights Agreement, the Company will be required to pay to each Purchaser an amount in cash, as partial liquidated damages, equal to 1.0 6 18 The forms of the Subscription Agreement, the Registration Rights Agreement, the Class A Warrant, the Class B Warrant and the warrant issued to the placement agent are filed as Exhibits to a Current Report on Form 8-K filed with the SEC on November 9, 2016, and the foregoing summaries of the terms of such documents are subject to, and qualified in their entirety by, the full text of such documents, which are incorporated herein by reference. Exchange of Summer 2016 Convertible Debentures In October 2016, the Company reached an agreement with two additional holders of the Summer 2016 Convertible Debentures pursuant to which such debentures will be exchanged for new short-term convertible notes (the “Exchange Notes”). The Exchange Notes shall have a principal amount totaling $ 95,813 10 March 31, 2017 13,876 Anti-Dilution Triggering Event The sale of Common Stock in November 2016 (see above) was completed at a unit price of $ 0.075 49,500,832 25,244,336 0.075 49,459,532 Agreement with Landlord On November 4, 2016, the Company reached an agreement with the landlord for its Morgantown, West Virginia facility for payment of past-due rent. The agreement stipulates that the Company will pay the amount due as of October 31, 2016, $ 90,801 September 2016 10% OID Secured Promissory Note On September 8, 2016, the Company entered into a Note Purchase Agreement with an Accredited Investor pursuant to which the investor purchased a 10% original issue discount secured promissory note of the Company in the principal face amount of $720,000 due October 15, 2016 for an aggregate purchase price of $650,000 (“September 2016 10% OID Secured Promissory Note”). The principal balance of $720,000 bears interest at a rate of 10% per annum, and was payable on the October 15, 2016 maturity date. The Company’s obligations to repay and otherwise perform its obligations under the September 2016 10% OID Secured Promissory Note are secured by a continuing first priority lien and security interest in the accounts receivable and inventory of the Company and its subsidiary, Protea Biosciences, Inc. (the “Subsidiary”) pursuant to the terms of a Security Agreement among the Company, the Subsidiary, and the Lender (the “Security Agreement”) and include the specific assets now owned or hereafter acquired of the Company and the Subsidiary listed on the Exhibit 1 to the Security Agreement. The Subsidiary also provided the Lender with a full recourse guaranty for the prompt performance of all obligations of the Company, pursuant to the terms of a guaranty agreement. As of the date of this report, the Company is in discussions with the investor regarding terms to extend the maturity date of the note and such investor has acknowledged that the Company is not currently in default under the note. If the Company is unable to successfully negotiate an extension to the note agreement, the Accredited Investor may assert all of its rights and remedies available under the Security Agreement and applicable law.

Gross Revenue (Tables)

Gross Revenue (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Revenue from External Customers by Products and Services [Table Text Block]	The Company recognizes revenue from three major components: molecular information services, LAESI® instrument platform and research products. Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Molecular information services $ 452,489 $ 206,601 $ 1,164,362 $ 596,309 LAESI® instrument platform 4,160 155,550 191,081 461,537 Research products 63,259 60,537 221,567 213,447 Gross revenue $ 519,908 $ 422,688 $ 1,577,010 $ 1,271,293

Fair Value of Financial Asset26

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Inputs, Instruments Classified in Shareholders' Equity, Quantitative Information [Table Text Block]	As of September 30, 2016, a range of key quantitative assumptions related to the Common Stock and warrants that include “down round protection” are as follows: Expected life (years) Risk-free rate Volatility Probability of a capital raise Derivative liabilities 0.25 – 4.50 0.29% and 0.77% 79.52 % 100 %
Fair Value, by Balance Sheet Grouping [Table Text Block]	The derivative liabilities measured at fair value on a recurring basis are summarized below: Fair value measurements as of September 30, 2016 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 4,097,278 $ – $ – $ 4,097,278 Derivative liabilities – Warrants 518,753 – – 518,753 Derivative liabilities – Convertible debentures 313,629 – – 313,629 Total $ 4,929,660 $ – $ – $ 4,929,660 Fair value measurements as of December 31, 2015 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 777,002 $ – $ – $ 777,002 Derivative liabilities – Warrants 185,399 – – 185,399 Total $ 962,401 $ – $ – $ 962,401
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis: Nine Months Ended September 30, 2016 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of January 1, 2016 $ 777,002 $ 185,399 $ – $ 962,401 Unrealized loss on derivative liabilities outstanding as of December 31, 2015 3,320,276 279,025 – 3,599,301 Fair value of variable conversion rate for convertible debentures issued in 2016 (a) – – 313,629 313,629 Fair value of derivative liabilities associated with other financial instruments issued in 2016 (b) – 54,329 – 54,329 Balance as of September 30, 2016 $ 4,097,278 $ 518,753 $ 313,629 $ 4,929,660 (a) See also Note 12 Debt (b) See also Note 15 Warrants

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at: September 30, 2016 December 31, 2015 Work-in-progress $ 135,902 $ 98,437 Finished goods 9,710 12,650 Total inventory $ 145,612 $ 111,087

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property Plant And Equipment Useful Life [Table Text Block]	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Equipment 5 – 10 years Vehicles 5 years Leasehold improvements Life of lease Software 3 years
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following: September 30, 2016 December 31, 2015 Lab equipment $ 6,526,399 $ 6,617,038 Computer equipment 552,423 540,212 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 Accumulated depreciation (4,725,229) (4,934,321) Property and equipment, net $ 2,757,571 $ 2,626,907

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Other current liabilities consist of the following at: September 30, 2016 December 31, 2015 Accrued expenses $ 158,850 $ 28,728 Accrued interest 117,130 108,731 Accrued warranty expense 54,293 50,000 Accrued payroll and benefits 148,890 124,183 Unearned revenue 72,086 79,666 Other payables and accrued expenses $ 551,249 $ 391,308

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Total outstanding debt, including capital lease obligations, are as follows (table excludes the outstanding balance of the bank line of credit as of December 31, 2015 because it was presented as a current liability at that time, as discussed in Note 9 Bank Line of Credit; table also excludes obligations to stockholders, which are detailed in Note 10 Obligations to Stockholders and presented as a separate line item on the Company’s Consolidated Balance Sheets): September 30, 2016 December 31, 2015 Note Payable to the WVDO $ 92,873 $ 100,656 Note Payable to the WVEDA (a) 143,312 143,312 Note Payable to the WVIJDC (b) 139,229 139,229 Note Payable to the WVEDA (a) 572,148 572,148 Note Payable to the WVIJDC (b) 581,987 581,987 Note Payable to the WVJITB 290,000 290,000 Note Payable to the WVJITB 300,000 300,000 Note Payable to the WVEDA (a) 168,362 168,362 Convertible notes (c) 2,982,964 – Capital leases 1,048,122 754,058 Total 6,318,997 3,049,752 Less: current portion (4,086,145) (1,323,594) Less: unamortized original-issue discount (50,554) – Less: unamortized debt issuance costs (344,705) – Long-term portion $ 1,837,593 $ 1,726,158 (a) West Virginia Economic Development Authority (b) West Virginia Infrastructure and Jobs Development Council (c) Includes convertible notes with an outstanding balance of $ 1,987,125
Schedule of Maturities of Long-term Debt [Table Text Block]	Future required minimum principal repayments over the next five years are as follows (same exclusions as noted for the table above): Future required minimum Year Ended December 31: principal payments 2016 $ 4,049,767 2017 746,508 2018 514,743 2019 449,246 2020 and thereafter 558,733 Total $ 6,318,997

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]	Shares Price Estimated issued and per Gross fair value at Par Additional outstanding share proceeds issuance value paid-in capital Balance as of December 31, 2015 133,146,250 Various $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 Issuance (a) 371,364 $ 0.25 – 92,841 37 92,804 Issuance (b) 108,696 $ 0.25 – 27,174 11 27,163 Issuance (c) 600,000 $ 0.25 – 150,000 60 149,940 Balance as of September 30, 2016 134,226,310 (d) $ 58,393,786 $ 2,629,318 $ 13,423 $ 61,010,060 (a) See above under Conversion of Accrued Interest and Accounts Payable (b) Shares issued in conjunction with the March 2016 Convertible Note (see Note 12 Debt) (c) See above under Advertising Services Agreement (d) Includes 21,214,642

Stock Options and Stock-Based32

Stock Options and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of stock option activity is as follows: Weighted average Weighted ave. remaining Stock options exercise price contractual life (years) Outstanding as of December 31, 2015 10,050,086 $ 0.69 7.26 Granted 3,350,000 $ 0.15 Exercised – $ – Cancelled or expired (1,594,216) $ 0.31 Outstanding as of September 30, 2016 10,800,086 $ 0.57 7.53 Exercisable as of December 31, 2015 4,938,664 $ 1.01 5.59 Exercisable as of September 30, 2016 5,204,317 $ 0.90 5.61
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information about stock options at September 30, 2016: Stock options outstanding Stock options exercisable Weighted Weighted Weighted average average average remaining contractual exercise exercise Exercise price Outstanding life (in years) price Exercisable price $ 0.15 3,250,000 – $ 0.25 1,573,336 576,264 $ 0.48 150,000 37,500 $ 0.50 79,000 79,000 $ 0.53 405,000 126,563 $ 0.55 3,312,000 2,354,240 $ 0.80 20,000 20,000 $ 1.25 150,000 150,000 $ 1.50 1,646,000 1,646,000 $ 2.00 214,750 214,750 $0.15 – $2.00 10,800,086 7.53 $ 0.58 5,204,317 $ 0.90
Schedule of Nonvested Share Activity [Table Text Block]	The following table summarizes the activity of the Company’s stock options that have not yet vested: Weighted average grant-date fair Stock options value (per option) Non-vested as of December 31, 2015 5,111,422 $ 0.153 Granted 3,350,000 $ 0.153 Forfeited (1,594,216) $ 0.314 Vested (1,038,437) $ 0.106 Non-vested as of September 30, 2016 5,828,769 $ 0.126
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense is as follows: Nine Months Ended September 30, 2016 2015 Selling, general, and administrative expense $ 164,860 $ 178,371 Research and development expense 10,443 29,600 Total stock-based compensation $ 175,303 $ 207,971
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the stock option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: Nine Months Ended September 30, 2016 2015 Weighted average risk-free interest rate 1.33 % 1.69 % Volatility factor 66.51 % 66.34 % Weighted average expected life (in years) 7.46 8 Dividend rate 0 % 0 %

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2016
Warrants [Abstract]
Schedule Of Warrant Activity [Table Text Block]	Weighted Weighted average average remaining exercise contractual life Warrants price (in years) Outstanding as of December 31, 2015 71,342,894 $ 0.77 2.375 Granted 15,803,751 $ 0.30 2.998 Exercised – $ – Cancelled or expired (4,200,375) $ 2.00 Outstanding as of September 30, 2016 82,946,270 (a) $ 0.61 1.984 (a) includes 57,488,533
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes information about warrants as of September 30, 2016: Warrants outstanding Weighted Weighted average average remaining contractual exercise Exercise price Outstanding life (in years) price $ 0.250 12,317,895 $ 0.310 7,500,000 $ 0.325 6,510,001 $ 0.350 14,831,098 $ 0.360 2,845,000 $ 0.400 1,630,000 $ 0.450 1,730,000 $ 0.500 2,250,523 $ 0.750 11,065,144 $ 0.800 1,415,000 $ 1.100 19,054,350 $ 1.120 263,750 $ 2.000 138,800 $ 2.200 98,320 $ 2.250 1,296,389 $0.250 – $2.25 82,946,270 1.984 $ 0.61

Supplemental Cash Flow Inform34

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The Company did not pay any income taxes during 2015 or the nine months ended September 30, 2016. Non-cash investing and financing activities Nine Months Ended September 30, 2016 2015 Equipment acquired under capital leases $ 605,227 $ 516,832 Debt converted to preferred stock $ – $ 550,260 Dividends paid in preferred stock $ – $ 156,056 Issuance of common stock upon conversion of accrued interest $ 92,841 $ – Issuance of common stock for services $ – $ – Issuance of common stock with short-term convertible notes $ 27,174 $ – Issuance of warrants with short-term convertible notes $ 31,747 $ – Warrants to be issued to Placement Agent $ 5,772 $ – Anti-dilution warrants to be issued $ 6,878 $ – Debt issuance costs $ 5,000 $ –

Description of Business and B35

Description of Business and Basis of Presentation (Details Textual) - USD ($)

Sep. 09, 2016

Sep. 08, 2016

Nov. 30, 2016

Nov. 18, 2016

Nov. 03, 2016

Sep. 26, 2016

May 27, 2016

Sep. 30, 2016

Sep. 30, 2015

Oct. 31, 2016

Aug. 31, 2016

Dec. 31, 2015

Nature of Business [Line Items]

Substantial Doubt about Going Concern, Conditions or Events

We will remain an emerging growth company for up to five years following our initial public offering, that is, until February 2019, although we will lose that status sooner if our revenues exceed $1 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June30.

Bank Overdrafts

$ 233,246

$ 0

Proceeds from Sale of Equity Method Investments

1,502,100

$ 0

Increase (Decrease) in Accounts Payable

552,906

175,543

Debt Instrument, Face Amount

0

Proceeds from Issuance of Common Stock

0

720,938

Estimated Number Of Common Stock Shares To Be Issued

3,100,000

Estimated Value Of Common Stock To Be Issued

$ 15,000,000

Proceeds from Issuance of Debt

2,886,000

$ 2,000,000

Long-term Line of Credit

$ 3,000,000

$ 3,000,000

Sale of Stock, Number of Shares Issued in Transaction

125,757

License Agreement Terms [Member]

Nature of Business [Line Items]

Accrued Liabilities

$ 1,301,710

Short Term Convertible Notes [Member]

Nature of Business [Line Items]

Debt Instrument, Maturity Date

Mar. 31, 2017

September 2016 OID Secured Promissory Note [Member]

Nature of Business [Line Items]

Debt Instrument, Face Amount

$ 720,000

Debt Instrument, Maturity Date

Oct. 15, 2016

Oct. 15, 2016

Debt Instrument, Interest Rate, Stated Percentage

10.00%

10.00%

Proceeds from Issuance of Debt

$ 650,000

Amendment To Note Purchase Agreement Terms, Description

the investor entered into an amendment to the Note Purchase Agreement whereby the investor agreed to extend the maturity date of the note to the earlier of (a) December 31, 2016 or (b) receipt by the Company of not less than $3,000,000 in gross proceeds from the private offering of units of the Companys Common Stock and warrants to purchase to purchase Common Stock.

Summer 2016 Notes [Member]

Nature of Business [Line Items]

Debt Instrument, Face Amount

$ 1,892,500

Debt Instrument, Maturity Date

Mar. 31, 2017

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Long-term Debt, Gross

$ 1,987,125

Unsecured Convertible Note [Member]

Nature of Business [Line Items]

Debt Instrument, Face Amount

$ 156,250

Debt Instrument, Maturity Date

Mar. 26, 2017

Debt Instrument, Interest Rate, Stated Percentage

20.00%

Proceeds from Issuance of Debt

$ 107,500

Long-term Debt, Gross

$ 125,000

OverDue Terms [Member]

Nature of Business [Line Items]

Increase (Decrease) in Accounts Payable

$ 1,608,934

Past Due 90 Days [Member]

Nature of Business [Line Items]

Increase (Decrease) in Accounts Payable

1,303,710

Subsequent Event [Member]

Nature of Business [Line Items]

Proceeds from Issuance of Common Stock

$ 0

$ 487,850

$ 1,119,530

Stock Issued During Period, Shares, New Issues

14,927,066

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

25,244,336

29,854,132

Expected Number Of Shares To Be Issued

49,500,832

Proceeds from Related Party Debt

$ 255,000

Subsequent Event [Member] | Summer 2016 Notes [Member]

Nature of Business [Line Items]

Debt Instrument, Face Amount

$ 91,250

Long-term Debt, Gross

$ 95,813

AzurRx BioPharma Inc [Member]

Nature of Business [Line Items]

Proceeds from Sale of Equity Method Investments

$ 1,502,100

Equity Method Investment, Ownership Percentage

1.70%

25.00%

Sale of Stock, Number of Shares Issued in Transaction

125,757

Common Stock, Capital Shares Reserved for Future Issuance

100,000

Sale of Stock, Price Per Share

$ 1

Gross Revenue (Details)

Gross Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Gross revenue	$ 519,908	$ 422,688	$ 1,577,010	$ 1,271,293
Molecular information services [Member]
Segment Reporting Information [Line Items]
Gross revenue	452,489	206,601	1,164,362	596,309
LAESI® instrument platform [Member]
Segment Reporting Information [Line Items]
Gross revenue	4,160	155,550	191,081	461,537
Research products [Member]
Segment Reporting Information [Line Items]
Gross revenue	$ 63,259	$ 60,537	$ 221,567	$ 213,447

Sales of Investment (Details Te

Sales of Investment (Details Textual) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Subsidiary or Equity Method Investee [Line Items]
Sale of Stock, Number of Shares Issued in Transaction				125,757
Preferred Stock, Par or Stated Value Per Share	$ 0.0001			$ 0.0001	$ 0.0001
Common Stock, Par or Stated Value Per Share	$ 0.0001			$ 0.0001	$ 0.0001
Preferred Stock, Conversion Basis			The conversion rate was 24,393.65 shares of AzurRx Common Stock per share of AzurRx Preferred Stock.
Common Stock, Shares Outstanding	134,226,310			134,226,310	133,146,250
AzurRx BioPharma Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	1.70%			1.70%
Common Stock, Shares Outstanding			100,749
Sale of Stock, Price Per Share	$ 1			$ 1
Common Stock, Capital Shares Reserved for Future Issuance	100,000			100,000
Convertible Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred Stock, Par or Stated Value Per Share			$ 0.0001
Common Stock, Par or Stated Value Per Share			$ 0.0001
Series A Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			71
Common Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	140,000	550,000	1,016,941
Sale of Stock, Consideration Received on Transaction	$ 190,000	$ 675,000	$ 637,100
Common Stock [Member] | Convertible Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Conversion of Stock, Shares Issued			1,731,949

Fair Value of Financial Asset38

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details) - Derivative Financial Instruments, Liabilities [Member]	9 Months Ended
	Sep. 30, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility	79.52%
Probability of a capital raise	100.00%
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected life (years)	3 months
Risk-free rate	0.29%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected life (years)	4 years 6 months
Risk-free rate	0.77%

Fair Value of Financial Asset39

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details 1) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	$ 4,929,660	$ 962,401
Derivative liabilities - Convertible debentures [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	313,629	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liabilities - Convertible debentures [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liabilities - Convertible debentures [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	4,929,660	962,401
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Convertible debentures [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	313,629
Derivative liabilities - Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	4,097,278	777,002
Derivative liabilities - Common Stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0	0
Derivative liabilities - Common Stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0	0
Derivative liabilities - Common Stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	4,097,278	777,002
Derivative liabilities - Warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	518,753	185,399
Derivative liabilities - Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0	0
Derivative liabilities - Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	0	0
Derivative liabilities - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	$ 518,753	$ 185,399

Fair Value of Financial Asset40

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details 2)	9 Months Ended
	Sep. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	$ 962,401
Balance as of September 30, 2016	4,929,660
Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	0
Unrealized loss on derivative liabilities outstanding as of December 31, 2015	0
Fair value of variable conversion rate for convertible debentures issued in 2016	313,629	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	0	[2]
Balance as of September 30, 2016	313,629
Derivative liabilities - Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	185,399
Unrealized loss on derivative liabilities outstanding as of December 31, 2015	279,025
Fair value of variable conversion rate for convertible debentures issued in 2016	0	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	54,329	[2]
Balance as of September 30, 2016	518,753
Derivative liabilities - Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	777,002
Unrealized loss on derivative liabilities outstanding as of December 31, 2015	3,320,276
Fair value of variable conversion rate for convertible debentures issued in 2016	0	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	0	[2]
Balance as of September 30, 2016	4,097,278
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	962,401
Unrealized loss on derivative liabilities outstanding as of December 31, 2015	3,599,301
Fair value of variable conversion rate for convertible debentures issued in 2016	313,629	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	54,329	[2]
Balance as of September 30, 2016	4,929,660
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of September 30, 2016	313,629
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	185,399
Balance as of September 30, 2016	518,753
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	777,002
Balance as of September 30, 2016	$ 4,097,278
[1]	See also Note [12] Debt
[2]	See also Note [15] Warrants

Fair Value of Financial Asset41

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details Textual)	Sep. 30, 2016$ / shares
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Share Price	$ 0.075	[1]
[1]	See also Note [15] Warrants

Net Loss per Share (Details Tex

Net Loss per Share (Details Textual) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Weighted Average Number of Shares Outstanding, Basic and Diluted	133,824,867	115,839,765	133,605,888	105,923,915
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			98,285,387	86,556,934

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Work-in-progress	$ 135,902	$ 98,437
Finished goods	9,710	12,650
Total inventory	$ 145,612	$ 111,087

Property and Equipment (Details

Property and Equipment (Details)	9 Months Ended
	Sep. 30, 2016
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Vehicle [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Life of lease

Property and Equipment (Detai45

Property and Equipment (Details 1) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Lab equipment	$ 6,526,399	$ 6,617,038
Computer equipment	552,423	540,212
Office equipment	191,248	191,248
Leasehold improvements	212,730	212,730
Accumulated depreciation	(4,725,229)	(4,934,321)
Property and equipment, net	$ 2,757,571	$ 2,626,907

Property and Equipment (Detai46

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Total	$ 177,359	$ 176,561	$ 496,487	$ 532,616

Bank Line of Credit (Details Te

Bank Line of Credit (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jun. 20, 2016	Sep. 30, 2016	Sep. 08, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity (in dollars)		$ 3,000,000
Line of Credit Facility, Interest Rate Description		The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum.
Line of Credit Facility, Amount Outstanding (in dollars)		$ 3,000,000		$ 3,000,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Maturity Date	Jul. 12, 2018
September 2016 OID Secured Promissory Note [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Maturity Date		Oct. 15, 2016
Debt Instrument, Interest Rate, Stated Percentage		10.00%	10.00%

Obligations to Stockholders (De

Obligations to Stockholders (Details Textual) - USD ($)	1 Months Ended				9 Months Ended
	Nov. 30, 2016	Nov. 14, 2016	Jul. 31, 2016	Jun. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	May 31, 2016	Dec. 31, 2015
Loans Payable to Stockholders [Line Items]
Repayments of Related Party Debt		$ 9,164			$ 5,444	$ 0
Due to Officers or Stockholders, Current					2,710,220			$ 2,574,500
Interest Payable, Current					117,130			$ 108,731
Interest Expense [Member]
Loans Payable to Stockholders [Line Items]
Repayments of Notes Payable				$ 12,500
Interest Bearing Promissory Notes [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross							$ 200,000
Due to Officers or Stockholders, Current					1,111,556
Debt Instrument, Periodic Payment, Principal			$ 12,500
Debt Instrument, Periodic Payment, Interest			$ 5,444
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid					194,556
Interest Payable, Current					4,864
Non-Interest Bearing Promissory Notes [Member]
Loans Payable to Stockholders [Line Items]
Due to Officers or Stockholders, Current					1,598,664
Subsequent Event [Member]
Loans Payable to Stockholders [Line Items]
Proceeds from Related Party Debt	$ 255,000
Directors and Stock holders [Member]
Loans Payable to Stockholders [Line Items]
Proceeds from Related Party Debt					235,540
Three Directors [Member]
Loans Payable to Stockholders [Line Items]
Repayments of Related Party Debt					94,375
Stockholders [Member]
Loans Payable to Stockholders [Line Items]
Repayments of Related Party Debt					$ 52,500

Other Current Liabilities (Deta

Other Current Liabilities (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Payables And Accruals [Line Items]
Accrued expenses	$ 158,850	$ 28,728
Accrued interest	117,130	108,731
Accrued warranty expense	54,293	50,000
Accrued payroll and benefits	148,890	124,183
Unearned revenue	72,086	79,666
Other payables and accrued expenses	$ 551,249	$ 391,308

Debt (Details)

Debt (Details) - USD ($)		Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		$ 6,318,997	$ 3,049,752
Less: current portion		(4,086,145)	(1,323,594)
Less: unamortized original-issue discount		(50,554)	0
Less: unamortized debt issuance costs		(344,705)	0
Long-term portion		1,837,593	1,726,158
Note Payable To West Virginia Development Office [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		92,873	100,656
Note Payable To West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	143,312	143,312
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[2]	139,229	139,229
Note Payable To West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	572,148	572,148
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[2]	581,987	581,987
Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		290,000	290,000
Note Payable To West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		300,000	300,000
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	168,362	168,362
Capital leases [Member]
Debt Instrument [Line Items]
Capital Lease Obligations		1,048,122	754,058
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[3]	$ 2,982,964	$ 0
[1]	West Virginia Economic Development Authority
[2]	West Virginia Infrastructure and Jobs Development Council
[3]	Includes convertible notes with an outstanding balance of $1,987,125 that include anti-dilution protection

Debt (Details 1)

Debt (Details 1) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Future Required Minimum Principal Repayments
2,016	$ 4,049,767
2,017	746,508
2,018	514,743
2,019	449,246
2020 and thereafter	558,733
Total	$ 6,318,997	$ 3,049,752

Debt (Details Textual)

Debt (Details Textual) - USD ($)		Sep. 08, 2016	Sep. 06, 2016	Mar. 04, 2016	Oct. 31, 2016	Sep. 26, 2016	Jul. 29, 2016	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Nov. 30, 2016	Nov. 03, 2016	Sep. 09, 2016	Jul. 31, 2016	Mar. 31, 2016	Apr. 30, 2012	Mar. 31, 2012
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 0	$ 0
Debt Conversion, Converted Instrument, Shares Issued											205,791
Debt Instrument, Unamortized Discount											$ 344,705	344,705		$ 0
Conversion of convertible debt												0	$ 550,260
Payments of Debt Issuance Costs												330,141	$ 309,345
Stock Issued During Period, Value, Conversion of Convertible Securities												27,174
Debt and Capital Lease Obligations, Total											$ 6,318,997	$ 6,318,997		3,049,752
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount												98,285,387	86,556,934
Subsequent Event [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															25,244,336	29,854,132
Debt Instrument, Convertible, Conversion Price															$ 0.075
Placement Agent [Member]
Debt Instrument [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure																	$ 54,447
West Virginia Jobs Investment Trust Board [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Warrants														10,000,000
Investor [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											6,510,000	6,510,000
Warrants Not Settleable in Cash, Fair Value Disclosure																	233,345
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.325	$ 0.325
Common Stock [Member]
Debt Instrument [Line Items]
Equity, Fair Value Disclosure											$ 27,174	$ 27,174
Stock Issued During Period, Value, Conversion of Convertible Securities												$ 11
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount												21,214,642
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Debt Instrument, Periodic Payment											51,613	$ 150,000
Debt Instrument, Face Amount							$ 63,750
Debt Conversion, Converted Instrument, Shares Issued				108,696
Unsecured Debt Original Issue Discount Percentage				23.00%
Proceeds from Issuance of Unsecured Debt				$ 500,000
Warrants Not Settleable in Cash, Fair Value Disclosure																			$ 12,773
Accretion Expense											$ 38,019	$ 104,947
Legal Fees				5,000
Conversion of convertible debt				$ 27,174
Debt Conversion, Converted Instrument, Warrants or Options Issued				1,637,500
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.75
Percentage of Closing Bid Price				70.00%
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											2,010,250	2,010,250
Repayments of Unsecured Debt			$ 655,000
Debt Instrument Original Issue Discount Percentage							20.00%
Proceeds from Convertible Debt							$ 51,000
Debt and Capital Lease Obligations, Total	[1]										$ 2,982,964	$ 2,982,964		0
Unsecured Convertible Debentures [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date					Mar. 31, 2017
Conversion of convertible debt					$ 1,987,125
Debt Instrument, Interest Rate, Effective Percentage					10.00%
Unsecured Convertible Debentures [Member] | Placement Agent [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						109,375	1,409,625
Warrants Not Settleable in Cash, Fair Value Disclosure							$ 3,077
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 239	$ 0.25
Payments of Debt Issuance Costs						$ 15,000	$ 191,400
Class of Warrant or Right, Warrants Term							3 years
Unsecured Convertible Debentures [Member] | Investor [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross (in dollars)						$ 125,000
Debt Instrument, Maturity Date						Mar. 26, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						468,750
Debt Instrument, Convertible, Conversion Price						$ 0.25	$ 0.325
Debt Instrument, Face Amount						$ 156,250
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 1,792	$ 731
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.325
Debt Instrument Original Issue Discount Percentage						20.00%
Class of Warrant or Right, Percentage of Securities Called by Warrants or Rights						85.00%	75.00%
Class of Warrant or Right, Warrants Term							3 years
Convertible Note and Warrant [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.25	$ 0.25
Payments of Debt Issuance Costs												$ 2,456
Placement Agent Commissions Paid												$ 60,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											491,250	491,250
Convertible Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount				$ 150,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount											1,987,125
September 2016 OID Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10.00%									10.00%	10.00%
Debt Instrument, Maturity Date												Oct. 15, 2016
Debt Instrument, Face Amount		$ 720,000
Secured Debt Original Issue Discount, Percentage		10.00%
Proceeds from Issuance of Secured Debt		$ 650,000
Second Quarter Two Thousand Sixteen Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage											10.00%	10.00%
Debt Instrument, Face Amount											$ 1,950,000	$ 1,950,000
Unsecured Debt Original Issue Discount Percentage											20.00%
Proceeds from Issuance of Unsecured Debt											$ 1,560,000
Debt Instrument ,Original Issue Discount											$ 390,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger											85.00%
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Placement Agent [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.25	$ 0.25
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Jan 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 605,000	$ 605,000
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Mar 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 481,250	481,250
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Dec 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date											Dec. 31, 2016
Debt Instrument, Face Amount											$ 415,000	415,000
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Nov 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date											Nov. 30, 2016
Debt Instrument, Face Amount											$ 448,750	448,750
Second Quarter 2016 Convertible Debentures [Member] | Warrant [Member] | Exchange Notes [Member] | Investor [Member]
Debt Instrument [Line Items]
Derivative, Fair Value, Net																	$ 287,792
Notes Payable to West Virginia Development Office [Member]
Debt Instrument [Line Items]
Notes Payable											$ 64,278	$ 64,278						$ 16,070
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross (in dollars)																					$ 290,000
Debt Instrument, Face Amount																					$ 290,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											1,180,000	1,180,000
Debt and Capital Lease Obligations, Total											$ 290,000	$ 290,000		290,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross (in dollars)																				$ 400,000
Debt Instrument, Face Amount																				$ 300,000
Debt and Capital Lease Obligations, Total											$ 300,000	300,000		300,000
Capital Leases [Member]
Debt Instrument [Line Items]
Leases Secured Equipment cost								$ 549,543				$ 1,868,809
Capital Leases [Member] | Maximum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate											9.45%	9.45%
Capital Leases [Member] | Minimum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate											5.04%	5.04%
Convertible Promissory Notes with WVJITB [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount														$ 200,000
Debt Conversion, Converted Instrument, Warrants or Options Issued														590,000
Payments of Debt Issuance Costs									$ 2,478	$ 2,478
Common Stock Exercise Price														$ 0.40
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 156,250
[1]	Includes convertible notes with an outstanding balance of $1,987,125 that include anti-dilution protection

Common Stock (Details)

Common Stock (Details) - USD ($)		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015
Class of Stock [Line Items]
Issuance of stock, Gross Proceeds (in dollars)		$ 0	$ 720,938
Beginning Balance		13,315
Issuance of stock for services		150,000
Ending Balance		$ 13,423
Common Stock [Member]
Class of Stock [Line Items]
Balance (in shares)		133,146,250
Issuance of stock, Shares issued (in shares)		600,000
Balance (in shares)	[1]	134,226,310
Price Per Share, Beginning Balance (in dollars per share)		Various
Gross Proceeds, Beginning Balance (in dollars)		$ 58,393,786
Gross Proceeds, Ending Balance (in dollars)		58,393,786
Estimated fair value at issuance, Beginning Balance (in dollars)		2,359,303
Estimated fair value at issuance, Ending Balance (in dollars)		2,629,318
Beginning Balance		13,315
Issuance of stock for services		60
Ending Balance		13,423
Additional Paid in Capital, Beginning Balance (in dollars)		60,740,153
Additional Paid in Capital, Ending Balance (in dollars)		$ 61,010,060
Issuance of stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[2]	371,364
Stock Options exercised, Price Per Share (in dollars per share)	[2]	$ 0.25
Issuance of stock, Gross Proceeds (in dollars)	[2]	$ 0
Issuance of stock, Estimated fair value at issuance (in dollars)	[2]	92,841
Issuance of stock for services	[2]	37
Issuance of stock, Additional Paid in Capital (in dollars)	[2]	$ 92,804
Issuance of stock 1 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[3]	108,696
Stock Options exercised, Price Per Share (in dollars per share)	[3]	$ 0.25
Issuance of stock, Gross Proceeds (in dollars)	[3]	$ 0
Issuance of stock, Estimated fair value at issuance (in dollars)	[3]	27,174
Issuance of stock for services	[3]	11
Issuance of stock, Additional Paid in Capital (in dollars)	[3]	$ 27,163
Issuance of stock 2 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[4]	600,000
Stock Options exercised, Price Per Share (in dollars per share)	[4]	$ 0.25
Issuance of stock, Gross Proceeds (in dollars)	[4]	$ 0
Issuance of stock, Estimated fair value at issuance (in dollars)	[4]	150,000
Issuance of stock for services	[4]	60
Issuance of stock, Additional Paid in Capital (in dollars)	[4]	$ 149,940
[1]	includes 57,488,533 warrants that contain an anti-dilution provision
[2]	See above under Conversion of Accrued Interest and Accounts Payable
[3]	Shares issued in conjunction with the March 2016 Convertible Note (see Note 12 Debt)
[4]	See above under Advertising Services Agreement

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Jul. 31, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Nov. 30, 2016	Oct. 21, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Shares Authorized Total			260,000,000	260,000,000
Common Stock, Shares Authorized			250,000,000	250,000,000				250,000,000
Preferred Stock, Shares Authorized			10,000,000	10,000,000				10,000,000
Paid-In-Kind Interest				$ 0	$ 192,785
Debt Conversion, Original Debt, Amount				$ 51,448
Common Stock, Par or Stated Value Per Share			$ 0.0001	$ 0.0001				$ 0.0001
Preferred Stock, Par or Stated Value Per Share			$ 0.0001	$ 0.0001				$ 0.0001
Payments of Debt Issuance Costs				$ 330,141	$ 309,345
Debt Conversion, Converted Instrument, Shares Issued			205,791
Stock Issued During Period, Value, Issued For Services				$ 150,000
Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares				0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount				98,285,387	86,556,934
Accounts Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount				$ 9,781
Debt Instrument, Convertible, Conversion Price			$ 0.25	$ 0.25
Interest Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount				$ 41,667
Media Advertising [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services	300,000
Stock Issued During Period, Value, Issued For Services	$ 75,000
Convertible Notes Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Description		In February 2016, the Companys Board of Directors authorized the conversion of an aggregate of $33,333 of accrued interest on promissory notes issued by the Company to Summit and $8,060 of account payable (or a total of $41,393) by the Company to Summit, into 165,573 shares of Common Stock at the rate of $0.25 per share.
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		450,000	450,000	450,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.40
Payments of Debt Issuance Costs		$ 945
Term Of Warrants		5 years
Media Advertising Agreement [Member]
Class of Stock [Line Items]
Management Fee Expense				$ 37,500
Common Stock [Member]
Class of Stock [Line Items]
Paid-In-Kind Interest		$ 33,333
Accounts Payable		$ 8,060
Stock Issued During Period, Shares, Issued For Services				600,000
Stock Issued During Period, Value, Issued For Services				$ 60
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount				21,214,642
Common Stock [Member] | Media Advertising Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services				150,000
Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized							500,000,000
Preferred Stock, Shares Authorized							10,000,000
Common Stock, Par or Stated Value Per Share							$ 0.0001
Preferred Stock, Par or Stated Value Per Share							$ 0.0001
Debt Instrument, Convertible, Conversion Price						$ 0.075

Stock Options and Stock-Based55

Stock Options and Stock-Based Compensation (Details) - Employee Stock Option [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding	10,050,086
Shares, Granted	3,350,000
Shares, Exercised	0
Shares, Cancelled or expired	(1,594,216)
Shares, Outstanding	10,800,086	10,050,086
Shares Exercisable	5,204,317	4,938,664
Weighted Average Exercise Price, Outstanding	$ 0.69
Weighted Average Exercise Price, Granted	0.15
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	0.31
Weighted Average Exercise Price, Outstanding	0.57	$ 0.69
Weighted Average Exercise Price, Exercisable	$ 0.90	$ 1.01
Weighted ave. remaining contractual life (years), Outstanding	7 years 6 months 11 days	7 years 3 months 4 days
Weighted ave. remaining contractual life (years), Exercisable	5 years 7 months 10 days	5 years 7 months 2 days

Stock Options and Stock-Based56

Stock Options and Stock-Based Compensation (Details 1)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Exercise Price 0.15 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.15
Options Outstanding (in shares)	3,250,000
Options Exercisable (in shares)	0
Exercise Price 0.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.25
Options Outstanding (in shares)	1,573,336
Options Exercisable (in shares)	576,264
Exercise Price 0.48 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.48
Options Outstanding (in shares)	150,000
Options Exercisable (in shares)	37,500
Exercise Price 0.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.50
Options Outstanding (in shares)	79,000
Options Exercisable (in shares)	79,000
Exercise Price 0.53 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.53
Options Outstanding (in shares)	405,000
Options Exercisable (in shares)	126,563
Exercise Price 0.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.55
Options Outstanding (in shares)	3,312,000
Options Exercisable (in shares)	2,354,240
Exercise Price 0.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.80
Options Outstanding (in shares)	20,000
Options Exercisable (in shares)	20,000
Exercise Price 1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.25
Options Outstanding (in shares)	150,000
Options Exercisable (in shares)	150,000
Exercise Price 1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.50
Options Outstanding (in shares)	1,646,000
Options Exercisable (in shares)	1,646,000
Exercise Price 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	214,750
Options Exercisable (in shares)	214,750
Exercise Price 0.15 - 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Limit (in dollars per share) | $ / shares	$ 0.15
Options Outstanding, Exercise Price, Upper Limit (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	10,800,086
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	7 years 6 months 11 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.58
Options Exercisable (in shares)	5,204,317
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.90

Stock Options and Stock-Based57

Stock Options and Stock-Based Compensation (Details 2) - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Non-vested, Beginning Balance	5,111,422
Shares, Granted	3,350,000
Shares, Forfeited	(1,594,216)
Shares, Vested	(1,038,437)
Shares, Non-vested at Ending Balance	5,828,769
Weighted Average grant-date fair value, Non-vested, Beginning Balance	$ 0.153
Weighted average grant-date fair Value, Granted	0.153	$ 0.31
Weighted average grant-date fair value, Forfeited	0.314
Weighted average grant-date fair value, Vested	0.106
Weighted average grant-date fair value, Non-vested, Ending Balance	$ 0.126

Stock Options and Stock-Based58

Stock Options and Stock-Based Compensation (Details 3) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 175,304	$ 207,971
Selling, general and administrative expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	164,860	178,371
Research and development expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 10,443	$ 29,600

Stock Options and Stock-Based59

Stock Options and Stock-Based Compensation (Details 4)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate	1.33%	1.69%
Volatility factor	66.51%	66.34%
Weighted average expected life (in years)	7 years 5 months 16 days	8 years
Dividend rate	0.00%	0.00%

Stock Options and Stock-Based60

Stock Options and Stock-Based Compensation (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2012	Dec. 31, 2002
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award Estimated Fair Value of Stock Price (in dollars per share)	$ 0.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in dollars)	$ 175,304	$ 207,971
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.153	$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Expected Term	2 years 8 months 19 days
Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested And Expected To Vest Fair Value	$ 674,803
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Equity Incentive Plan 2002 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			4,150,000	450,000
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	12,500,000

Warrants (Details)

Warrants (Details) - Warrant [Member] - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2016		Dec. 31, 2015
Class of Warrant or Right [Line Items]
Shares, Outstanding at December 31, 2015	71,342,894
Shares, Granted	15,803,751
Shares, Exercised	0
Shares, Cancelled or expired	(4,200,375)
Shares, Outstanding at September 30, 2016	82,946,270	[1]	71,342,894
Weighted Average Exercise Price, Outstanding at December, 2015	$ 0.77
Weighted Average Exercise Price, Granted	0.30
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	2
Weighted Average Exercise Price,Shares, Outstanding at September 30, 2016	$ 0.61		$ 0.77
Weighted Average Remaining Contractual Life (in years), Outstanding	1 year 11 months 24 days		2 years 4 months 15 days
Weighted Average Remaining Contractual Life (in years), Granted	2 years 11 months 29 days
[1]	includes 57,488,533 warrants that contain an anti-dilution provision

Warrants (Details 1)

Warrants (Details 1) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	82,946,270
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	1 year 11 months 24 days	2 years 4 months 15 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.61	$ 0.77
Exercise Price 0.250
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.250
Warrants Outstanding (in shares)	12,317,895
Exercise Price 0.310
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.310
Warrants Outstanding (in shares)	7,500,000
Exercise Price 0.325
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.325
Warrants Outstanding (in shares)	6,510,001
Exercise Price 0.350
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.350
Warrants Outstanding (in shares)	14,831,098
Exercise Price 0.360
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.360
Warrants Outstanding (in shares)	2,845,000
Exercise Price 0.400
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.400
Warrants Outstanding (in shares)	1,630,000
Exercise Price0.450
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.450
Warrants Outstanding (in shares)	1,730,000
Exercise Price 0.500
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.500
Warrants Outstanding (in shares)	2,250,523
Exercise Price 0.750
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.750
Warrants Outstanding (in shares)	11,065,144
Exercise Price 0.800
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.800
Warrants Outstanding (in shares)	1,415,000
Exercise Price 1.100
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.100
Warrants Outstanding (in shares)	19,054,350
Exercise Price 1.120
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.120
Warrants Outstanding (in shares)	263,750
Exercise Price 2.000
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2
Warrants Outstanding (in shares)	138,800
Exercise Price 2.200
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.200
Warrants Outstanding (in shares)	98,320
Exercise Price 2.250
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.250
Warrants Outstanding (in shares)	1,296,389
Exercise Price 0.250 - 2.25 | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.25
Exercise Price 0.250 - 2.25 | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.250

Warrants (Details Textual)

Warrants (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 26, 2016	Sep. 09, 2016	Jul. 29, 2016	May 20, 2016	Mar. 31, 2016	Mar. 04, 2016	Feb. 29, 2016
Class of Warrant or Right [Line Items]
Interest Expense, Other		$ 49,894
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		98,285,387	86,556,934
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	82,946,270	82,946,270
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		57,488,533
Convertible Notes Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.40
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	450,000	450,000								450,000
Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.75
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	2,010,250	2,010,250
Accretion Expense	$ 38,019	$ 104,947
Warrants Not Settleable in Cash, Fair Value Disclosure								$ 12,773
Investor [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.325	$ 0.325
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,510,000	6,510,000
Warrants Not Settleable in Cash, Fair Value Disclosure					$ 233,345
Investor [Member] | Warrant [Member]
Class of Warrant or Right [Line Items]
Derivative, Fair Value, Net	$ 28,202	$ 28,202
Investor [Member] | Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.325
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				468,750
Warrants Not Settleable in Cash, Fair Value Disclosure				$ 1,792		$ 731
St. George Investments [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.25
Fair Value Adjustment of Warrants		6,879
Accretion Expense		$ 104,947
Placement Agent [Member]
Class of Warrant or Right [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure					$ 54,447
Placement Agent [Member] | Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 239		$ 0.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				109,375		1,409,625
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 3,077
Convertible Promissory Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1,180,000	1,180,000
Minimum [Member] | St. George Investments [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							1,637,500
Maximum [Member] | St. George Investments [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							4,912,500

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 04, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)
Loss Contingencies [Line Items]
Accrued warranties		$ 54,293		$ 54,293		$ 50,000
Loss Contingency, Estimate of Possible Loss		213,032		213,032
Subsequent Event [Member]
Loss Contingencies [Line Items]
Minimum Base Rent Expenses	$ 90,801
George Washington University [Member]
Loss Contingencies [Line Items]
Royalty Expenses		4,765	$ 10,934	20,299	$ 31,145
License Costs				25,000
Minimum License Diligence Resources Year Two				12,500
Minimum License Diligence Resources After Year Two				20,000
License and Maintenance Revenue				$ 30,000
Royalties Percentage on Net Sales of Licensed Products				7.00%
Royalties Percentage on Combination Products for Combined Cumulative Net Sales				5.00%
Reduce Royalties Percentage After Net Sales of Licensed Products				6.00%
Reduce Royalties Percentage on Combination Products for Combined Cumulative After Net Sales				4.00%
Minimum Royalties Year One		1,500		$ 1,500
Minimum Royalties Year Two		2,500		2,500
Minimum Royalties Year Three		3,500		3,500
Minimum Royalties Year After Three Year		6,000		6,000
Accrued Royalties, Current		79,292		79,292
Accounts Payable, Current		118,046		118,046
Maximum Cumulative Net Sales Under Patent License Agreement				50,000,000
COAST Project [Member]
Loss Contingencies [Line Items]
Commitments Outstanding		24,500		24,500			$ 76,000	€ 60,000
REDIchip [Member]
Loss Contingencies [Line Items]
Royalty Expenses		$ 2,500		$ 5,500

Supplemental Cash Flow Inform65

Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Equipment acquired under capital leases	$ 605,227	$ 516,832
Debt converted to preferred stock	0	550,260
Dividends paid in preferred stock	0	156,056
Issuance of common stock upon conversion of accrued interest	92,841	0
Issuance of common stock for services	0	0
Issuance of common stock with short-term convertible notes	27,174	0
Issuance of warrants with short-term convertible notes	31,747	0
Warrants to be issued to Placement Agent	5,772	0
Anti-dilution warrants to be issued	6,878	0
Debt issuance costs	$ 5,000	$ 0

Supplemental Cash Flow Inform66

Supplemental Cash Flow Information (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Interest Paid	$ 190,752	$ 193,942

Evaluation of Subsequent Even67

Evaluation of Subsequent Events (Details Textual) - USD ($)	Sep. 08, 2016	Nov. 30, 2016	Nov. 18, 2016	Nov. 14, 2016	Nov. 03, 2016	Oct. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Nov. 04, 2016	Oct. 21, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Preferred Stock, Par or Stated Value Per Share							$ 0.0001				$ 0.0001
Common Stock, Par or Stated Value Per Share							$ 0.0001				$ 0.0001
Repayments of Related Party Debt				$ 9,164			$ 5,444	$ 0
Proceeds from Issuance of Common Stock							0	$ 720,938
Debt Instrument, Face Amount							$ 0
Common Stock, Shares Authorized							250,000,000				250,000,000
Preferred Stock, Shares Authorized							10,000,000				10,000,000
September 2016 OID Secured Promissory Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Maturity Date							Oct. 15, 2016
Debt Instrument, Interest Rate, Stated Percentage	10.00%						10.00%
Debt Instrument, Face Amount	$ 720,000
Proceeds from Issuance of Secured Debt	$ 650,000
Secured Debt Original Issue Discount, Percentage	10.00%
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt		$ 255,000
Preferred Stock, Par or Stated Value Per Share										$ 0.0001
Common Stock, Par or Stated Value Per Share										$ 0.0001
Stock Issued During Period, Shares, New Issues					14,927,066
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		25,244,336			29,854,132
Debt Instrument, Convertible, Conversion Price		$ 0.075
Proceeds from Issuance of Common Stock		$ 0	$ 487,850		$ 1,119,530
Due to Affiliate				3,039,056
Common Stock, Shares Authorized										500,000,000
Preferred Stock, Shares Authorized										10,000,000
Number Of Units Sold			48.79		63
Expected Number Of Shares To Be Issued		49,500,832
Class of Warrant or Right, Outstanding		49,459,532
Proceeds from Issuance of Private Placement						$ 5,000,000
Interest Percentage On Delay Payments						18.00%
Capital Lease Obligations									$ 90,801
Subsequent Event [Member] | Summer 2016 Convertible Debentures [Member]
Subsequent Event [Line Items]
Debt Instrument, Maturity Date						Mar. 31, 2017
Debt Instrument, Interest Rate, Effective Percentage						10.00%
Long-term Debt, Gross						$ 95,813
Amortization of Debt Discount (Premium)						$ 13,876
Subsequent Event [Member] | Advances From Stockholders [Member]
Subsequent Event [Line Items]
Due to Affiliate				$ 83,000
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Partial Liquidated Damages Percentage						1.00%
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Partial Liquidated Damages Percentage						6.00%
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Number Of Units Sold						500
Subsequent Event [Member] | Private Placement [Member] | Class A Warrnats [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.09
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						133,333.33
Subsequent Event [Member] | Private Placement [Member] | Class B Warrnats [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.1125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						133,333.33
Class Of Warrants Or Rights Expiration Term						5 years
Subsequent Event [Member] | Private Placement [Member] | Investor Warrants [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						133,333,334
Subsequent Event [Member] | Private Placement [Member] | Placement Agent [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.09
Payments of Stock Issuance Costs						$ 152,384
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						4,231,120
Subsequent Event [Member] | Private Placement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share						$ 0.0001
Stock Issued During Period, Shares, New Issues						66,666,667